Literature DB >> 1765976

High resolution computed tomography in early scleroderma lung disease.

J H Warrick1, M Bhalla, S I Schabel, R M Silver.   

Abstract

Seventeen patients with early systemic sclerosis (SSc) underwent high resolution computed tomography (HRCT) of the chest to evaluate dyspnea and/or abnormal pulmonary function tests (PFT). All patients were assigned a dyspnea score and each had routine chest radiography (CXR). Bronchoalveolar lavage (BAL) was performed on 10 patients. HRCT was abnormal in 15 patients (88%), while CXR was abnormal in only 10 patients (59%). Mediastinal lymphadenopathy was detected in 7 patients (41%). Disease duration, dyspnea score, and forced vital capacity (FVC) did not correlate with HRCT score. However, trends toward higher total BAL cell counts and higher BAL neutrophil counts were noted in patients with ground glass opacities on HRCT, and BAL lymphocyte counts were significantly higher in such cases. HRCT is superior to CXR for detecting early interstitial lung disease in SSc, but patient history and FVC correlate poorly with HRCT findings. Ground glass opacities on HRCT may reflect active alveolitis, and mediastinal lymphadenopathy associated with SSc lung disease may be a consequence of pulmonary inflammation.

Entities:  

Mesh:

Year:  1991        PMID: 1765976

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  61 in total

Review 1.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

2.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

Review 3.  [Pulmonary manifestations in rheumatic systemic diseases].

Authors:  T Schlossbauer; C Becker-Gaab; R Eibel
Journal:  Radiologe       Date:  2005-07       Impact factor: 0.635

4.  The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement.

Authors:  Benan Musellim; Hande Ikitimur; Hafize Uzun; Gul Ongen
Journal:  Rheumatol Int       Date:  2006-09-02       Impact factor: 2.631

Review 5.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

6.  Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: preliminary results.

Authors:  Alarico Ariani; Marina Carotti; Marwin Gutierrez; Elisabetta Bichisecchi; Walter Grassi; Gian Marco Giuseppetti; Fausto Salaffi
Journal:  Rheumatol Int       Date:  2013-08-15       Impact factor: 2.631

Review 7.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

8.  High-resolution computed tomography and rheumatoid arthritis: semi-quantitative evaluation of lung damage and its correlation with clinical and functional abnormalities.

Authors:  Baris Yilmazer; Sevtap Gümüştaş; Fulya Coşan; Nagihan İnan; Fatih Ensaroğlu; Gökhan Erbağ; Füsun Yıldız; Ayşe Çefle
Journal:  Radiol Med       Date:  2015-10-22       Impact factor: 3.469

9.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

10.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.